{"slideshow_credits": null, "snippet": "The request by the F.D.A. for more data on the heart risks of a diabetes drug will delay an important product for Novo Nordisk of Denmark.", "abstract": "Food and Drug Administration orders Danish drug maker Novo Nordisk to conduct additional clinical tests to assess potential heart risks associated with its new long-acting insulin Tresiba; move is major setback for company's 2013 outlook.", "section_name": "Business Day", "print_page": "9", "document_type": "article", "byline": {"person": [], "organization": "REUTERS", "original": "By REUTERS", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/02/11/business/fda-wants-more-tests-on-a-novo-nordisk-insulin-tresiba.html", "lead_paragraph": "The request by the F.D.A. for more data on the heart risks of a diabetes drug will delay an important product for Novo Nordisk of Denmark.", "headline": {"seo": "F.D.A. Wants More Tests on a Novo Nordisk Insulin, Tresiba", "main": "F.D.A. Demands More Tests of Novo Nordisk\u2019s New Insulin to Gauge Heart Risks", "print_headline": "F.D.A. Demands More Tests of Novo Nordisk\u2019s New Insulin to Gauge Heart Risks"}, "_id": "51187d9b00315214fbb8a4be", "word_count": "390", "multimedia": [], "pub_date": "2013-02-11T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Novo Nordisk A/S", "name": "organizations", "is_major": "Y", "rank": "1"}, {"value": "Food and Drug Administration", "name": "organizations", "is_major": "Y", "rank": "2"}, {"value": "Insulin", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "4"}, {"value": "Diabetes", "name": "subject", "is_major": "N", "rank": "5"}], "blog": [], "subsection_name": null, "type_of_material": "News"}